1. **Registrant Name**
   - Organization/Lobbying Firm: AstraZeneca Pharmaceuticals LP
   - Self Employed Individual: 

2. **Address**
   - Address1: 1800 CONCORD PIKE, P.O. BOX 15437
   - Address2: 
   - City: WILMINGTON
   - State: DE
   - Zip Code: 19850-5437
   - Country: USA

3. **Principal place of business (if different than line 2)**
   - City: 
   - State: 
   - Zip Code: 
   - Country: 

4a. **Contact Name**
   - b. Telephone Number
   - c. E-mail

5. **Senate ID#**
   - 54073-12

6. **House ID#**
   - 349750000

7. **Client Name**
   - Self
   - Check if client is a state or local government or instrumentality
   - AstraZeneca Pharmaceuticals LP

8. **Year**
   - Q1 (1/1 - 3/31): 
   - Q2 (4/1 - 6/30): 
   - Q3 (7/1 - 9/30): 
   - Q4 (10/1 - 12/31):

9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report

11. No Lobbying Issue Activity

12. **INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13**
   - **INCOME** relating to lobbying activities for this reporting period was:
     - Less than $5,000
     - $5,000 or more: $ __________
   - **EXPENSE** relating to lobbying activities for this reporting period were:
     - Less than $5,000
     - $5,000 or more: $ 600,000.00

13. **Organizations**
   - **INCOME**
   - **EXPENSE**

14. **REPORTING**
   - Method A. Reporting amounts using LDA definitions only
   - Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
   - Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

**Signature**
Digitally Signed By: Jamie Bell

**Date**
4/19/2018 6:28:09 PM
LOBBying activity. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

- American Health Care Act (HR 1628 House)
- SYNC Act - Medication Adherence (House)
- Value of Prescription Drugs
- Chronic Care - Drug Adherence and Continuity of Care (S 870)
- Price Transparency
- Oncology
- Oncology Care Model - CMS
- Personalized Medicine
- Affordable and Safe Prescription Drug Importation Act - S 469
- Cancer Care Payment Reform Act (S 463, H 1834)
- Innovative Payments
- Vaccines for Children program

17. House(s) of Congress and Federal agencies □ Check if None

- U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC)

18. Name of each individual who acted as a lobbyist in this issue area

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
<th>Covered Official Position (if applicable)</th>
<th>New</th>
</tr>
</thead>
<tbody>
<tr>
<td>Theresa</td>
<td>Jolivette</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>John</td>
<td>Myers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maria</td>
<td>Firvida</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Christine</td>
<td>Bloomquist</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Julie</td>
<td>Garner</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natalie</td>
<td>Morris</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laura</td>
<td>Okpala</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. Interest of each foreign entity in the specific issues listed on line 16 above □ Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Medicare Part D Coverage and Reimbursement
Medicare Part D Non-Interference
Legislative proposals to change Medicare Part D
Medicare Part B coverage and reimbursement
Medicaid Coverage

17. House(s) of Congress and Federal agencies □ Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
<th>Covered Official Position (if applicable)</th>
<th>New</th>
</tr>
</thead>
<tbody>
<tr>
<td>John</td>
<td>Myers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maria</td>
<td>Firvida</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Christine</td>
<td>Bloomquist</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Julie</td>
<td>Garner</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natalie</td>
<td>Morris</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laura</td>
<td>Okpala</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☑ Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House)
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870)
Medicare Telehealth Parity Act (H.R. 2550)
Electronic Prior Authorization Under Medicare Part D (House)
Cardiac Bundled Payment Model (HHS/CMMI)
Medicare Part D coverage and reimbursement
Value of Prescription Drugs, Senate & House
Prescription Drug Importation, Senate & House
Innovative Payment Models, Senate & House
Price Transparency, Senate & House
S. 251, Senate and House
CDC Asthma Funding, Senate

Legislative proposals to change Medicare Part D
Medicaid and 340B issues

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
<th>Covered Official Position (if applicable)</th>
<th>New</th>
</tr>
</thead>
<tbody>
<tr>
<td>Theresa</td>
<td>Jolivette</td>
<td></td>
<td></td>
<td>☐</td>
</tr>
<tr>
<td>John</td>
<td>Myers</td>
<td></td>
<td></td>
<td>☐</td>
</tr>
<tr>
<td>Maria</td>
<td>Firvida</td>
<td></td>
<td></td>
<td>☐</td>
</tr>
<tr>
<td>Natalie</td>
<td>Morris</td>
<td></td>
<td></td>
<td>☐</td>
</tr>
</tbody>
</table>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

<table>
<thead>
<tr>
<th>Address</th>
<th>State</th>
<th>Zip Code</th>
<th>Country</th>
</tr>
</thead>
</table>

21. Client new principal place of business (if different than line 20)

<table>
<thead>
<tr>
<th>Address</th>
<th>State</th>
<th>Zip Code</th>
<th>Country</th>
</tr>
</thead>
</table>

22. New General description of client’s business or activities
LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brantley</td>
<td>Carlson</td>
<td></td>
<td>John</td>
<td>Myers</td>
<td></td>
</tr>
</tbody>
</table>

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>Principal Place of Business</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>(city and state or country)</td>
</tr>
</tbody>
</table>

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

|   |   |   |   |   |   |

FOREIGN ENTITIES

27. Add the following foreign entities:

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>Principal place of business</th>
<th>Amount of contribution for lobbying activities</th>
<th>Ownership percentage in client</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>(city and state or country)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

|   |   |   |   |
|   |   |   |   |